Abstract
BACKGROUND:
Influenza causes approximately 3-5 million severe cases and 290,000-650,000 deaths annually, and oseltamivir is considered the first-line pharmacotherapy. Recent reports on neuropsychiatric events (NPEs) associated with the use of oseltamivir necessitated a systematic safety profile review.
OBJECTIVE:
To systematically review and meta-synthesize the evidence on the associations of oseltamivir with adverse NPEs and behavioral events.
METHODS:
We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/Medline, Embase, and Cochrane Library databases from inception through October 31, 2024. Studies comparing oseltamivir with other control groups for NPEs were analyzed. Outcomes were categorized into (1) affective disorders, (2) neuropsychiatric symptoms, (3) anxiety disorders, (4) schizophrenic/psychotic disorders, and (5) suicide-related behaviors.
RESULTS:
9 studies with 1,139-3,352,015 patients were identified. Oseltamivir significantly associated with a lower overall NPE incidence (risk ratio [RR] = 0.83; 95% CI = 0.72-0.97), except in patients younger than 20 years. Subgroup analyses showed significant association with a lower incidence risk in suicide attempts across all ages (RR = 0.60; 95% CI = 0.46-0.77) and in schizophrenia/psychotic disorders for patients younger than 20 years (RR = 0.75; 95% CI = 0.61-0.93).
CONCLUSIONS:
This is the first comprehensive meta-analysis examining the associations of oseltamivir with various NPEs and behavioral adverse events, and we found no evidence supporting increased risks of these adverse events with oseltamivir use.
Plain language summary
Influenza affects millions worldwide annually. Some case reports raised a concern that oseltamivir (Tamiflu) might cause mental health problems. We conducted a systematic review and meta-analysis and found that oseltamivir was not associated with increased risks of mental health conditions. Overall, oseltamivir may be safely used for patients with influenza infections.
Implications for managed care pharmacy
This meta-analysis provides robust evidence that oseltamivir is not associated with increased risks of neuropsychiatric events and may offer protective effects against mental health conditions. Oseltamivir may still be used as the first-line pharmacotherapy for patients with influenza infections. These findings may help reduce barriers to appropriate use of oseltamivir worldwide, potentially improving influenza management while minimizing unnecessary concerns about neuropsychiatric adverse events.
Influenza is a common respiratory infection, which results in 290,000-650,000 deaths annually.1 Severe illness requires hospitalizations, which occurs in 3-5 million people globally.1 Symptoms of influenza include a sudden onset of high fever, aching muscles, headache, severe fatigue, nonproductive cough, sore throat, and/or runny nose.1 Although most people infected with influenza recover within 1 or 2 weeks without requiring any medical treatment, some patients (eg, children, older adults, or those with other serious comorbid medical conditions) may experience exacerbation of existing conditions, along with neurologic complications, pneumonia, and even potentially preventable deaths.2–4
Antiviral medications are effective at reducing morbidity and mortality and are considered the first-line pharmacotherapy for influenza. US Food and Drug Administration–approved antiviral drugs currently include adamantanes (ie, rimantadine and amantadine), neuraminidase inhibitors (NAIs; ie, peramivir, zanamivir, and oseltamivir), and the polymerase acidic endonuclease inhibitor (baloxavir).5 Oseltamivir (Tamiflu) is the most frequently used antiviral agent for the treatment of influenza, and its use has increased since the epidemic of influenza A (H1N1) in 2009.4,6 Oseltamivir is an antiviral NAI with potent and selective competitive inhibition of the influenza virus neuraminidase, an enzyme necessary for viral replication.7 Oseltamivir phosphate is a prodrug that exerts pharmacologic activity when hydrolyzed in vivo to the active form, oseltamivir carboxylate. This activated form interferes with the release of progeny influenza virus from infected host cells and halts the spread of infection to new host cells. Oseltamivir reduces the duration of shedding and the viral titer and can shorten the length of symptoms by 0.5 to 3 days.8
Oseltamivir is generally well tolerated, regardless of age or comorbid medical conditions. Oseltamivir has been a critical pharmacotherapeutic intervention in influenza pandemics and may form the basis for the management of seasonal influenza infections and strategic planning for future influenza pandemics.9 The most common side effects of oseltamivir are nausea, vomiting, and epigastric discomfort, which occur in 10% to 15% of adults who receive a therapeutic dose (ie, 75 mg twice a day).10,11 However, reports of suicidal ideation or suicide attempts, delirium, and/or other psychiatric events, particularly among children and adolescents, have been documented and raised concerns about the safety of oseltamivir.12 In addition, several other case reports have documented other neuropsychiatric events (NPEs) associated with oseltamivir.13–17 The most reported NPEs included behavioral conditions (eg, psychosis) and delusions/perceptual disturbances, although delirium or delirium-like events have also been commonly reported.14
Previous studies on the association between oseltamivir and adverse NPEs are limited; in particular, differences in study designs, sample sizes, and analytic methods make it difficult to draw consistent conclusions. A systematic literature review and meta-analysis is needed to overcome these methodological issues and provide clear evidence on the safety profiles of oseltamivir. In this study, we conducted a systematic review and meta-analysis to evaluate the associations of oseltamivir with adverse neuropsychiatric and behavioral events. To our knowledge, this is the first study to provide robust evidence on the safety profiles in the use of oseltamivir. Our findings will facilitate clinical decision-making for treating patients with influenza infections.
Methods
The protocol for this systematic review and meta-analysis was registered in PROSPERO (#CRD42024611337), and we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1 (650.6KB, pdf) , available in online article).18
DATA SOURCES AND LITERATURE SEARCH
A comprehensive literature search was conducted using the PubMed/Medline, Embase, and Cochrane Library databases for original research articles published from inception through October 31, 2024. The search strategy incorporated Medical Subject Headings terms and text keywords (eg, Tamiflu, NPE, suicide, suicide attempted, suicidal ideation, depression, aggression, anxiety, and irritable mood) related to oseltamivir and NPEs. Search terms were combined using Boolean operators (“AND” and “OR”) with detailed search strategies for each database presented in Supplementary Table 2 (650.6KB, pdf) .
INCLUSION AND EXCLUSION FOR STUDY SELECTION
The inclusion criteria were as follows: (1) patients with influenza virus infection or those receiving oseltamivir for prophylaxis; (2) intervention group was those treated with oseltamivir, and control groups consisted of those (a) without any treatment, (b) with antiviral medication(s) other than oseltamivir, and (c) with treatment other than antivirals ; and (3) outcomes defined as NPEs (eg, depression and anxiety).
Duplicated articles were removed using EndNote (version 20, Thomson Reuters). We excluded nonoriginal articles (ie, editorials, conference abstracts, commentary articles, case reports, case series, and reviews), non-English publications, articles without full-text availability, and studies lacking quantitative data on NPE frequency or risk estimates (eg, odds ratio, hazard ratio, or relative risk).
Two independent investigators (H.S.J. and Y.W.L.) reviewed abstracts and full texts to determine study eligibility and extracted data separately. Disagreements were resolved through discussion with all investigators.
DATA EXTRACTION
Data extracted from each study included the first author, publication year, country, study design, database sources, characteristics of study participants (eg, sample size, age, and sex), and NPE frequencies or risk estimates.
During initial data collection, we comprehensively gathered all outcome variables meeting the inclusion/exclusion criteria. Outcomes reported with different terminology across studies were standardized using preferred terms from the Medical Dictionary for Regulatory Activities. Non-NPE outcomes (eg, encephalitis, epilepsy and seizures, movement disorders, sleep disorders, and stroke) were excluded from the final analysis after consultation with a psychiatric specialist (T.G.R.).
The collected outcomes were based on the reviewed studies; the NPE outcomes were categorized into 5 major groups: (1) affective disorders (eg, depression and bipolar disorder), (2) neuropsychiatric symptoms (eg, altered state of consciousness, delirium, hallucination, and neuropsychiatric symptoms), (3) anxiety or stress disorders (ie, anxiety and acute stress disorders), (4) schizophrenia or psychotic disorders (eg, schizophrenic spectrum disorders and other psychotic disorders), and (5) suicide and suicidal behaviors (eg, suicidal ideation and suicide attempts).
STATISTICAL ANALYSIS
Statistical analyses were performed using the meta package in R software (version 4.3.1; R Foundation) to calculate pooled risk ratios (RRs) and 95% CIs. For individual studies reporting risk estimates, we used the reported values directly. For studies reporting only frequencies, we calculated expected values to derive RRs.19
For contingency tables containing zero cells, we applied a continuity correction approach by adding 0.5 to all cells to prevent computational errors.20 This correction was applied to 36 zero-cell occurrences. For studies with varying follow-up periods, we standardized the analysis using the most common duration of 14 days.
Because 5 main outcome groups were classified using multiple symptoms and effect sizes, we used a 2-stage meta-analysis. In the first stage, we obtained the overall effect size estimate of multiple measures within the study using a 3-level meta-analysis.21 In the second stage, we pooled and obtained the overall effect size estimate using 1 effect size from each study. This approach avoids potential duplication of the samples included.22
We used both the Cochrane Q and I2 statistics to quantify the proportions of heterogeneity caused by within- and between-study variations.20 To adequately estimate the overall effect sizes, RRs with their corresponding 95% CIs were calculated using fixed- or random-effects models depending on the model assumptions. Generally, a random-effects model was used when the I2 statistic was greater than 50%, and a fixed-effects model was used when the I2 statistic was less than 50%. However, a nonsignificant chi-square test indicated a lack of evidence for heterogeneity but did not necessarily imply homogeneity because there may have been insufficient power to detect heterogeneity. Moreover, in this study, several symptoms were grouped from several studies, so we reported it as a random-effect model.
We also conducted moderator analyses using meta-regression analyses by study sample size, male sex (%), study design (ie, randomized controlled trial [RCT], cohort, and case-crossover), and countries (ie, the United States, Korea, and multinational). When identifying potential moderators, we used the variance of the true effects using a restricted maximum likelihood estimator.23
Statistical significance was set at two-sided P less than 0.05. Publication bias was assessed using funnel plots.
QUALITY ASSESSMENT
The Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool was used to assess the quality of included nonrandomized studies. Although Jones et al24 analyzed data from RCTs, their study was classified as nonrandomized as it was a pooled analysis of data from 4 previous clinical trials rather than a primary randomized investigation. ROBINS-I comprises 7 domains: confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of reported results. Risk of bias for each domain was rated as no information or low, moderate, or serious bias.25
Results
STUDY SELECTION AND INCLUDED STUDIES
The database search identified 640 articles: PubMed/Medline (n = 52), EMBASE (n = 582), and Cochrane Library (n = 6). We excluded 550 articles after screening titles and abstracts and 51 duplicates. Of the remaining 39 articles, we excluded studies because of unavailable full text (n = 10), no outcomes of interest (n = 8), nonoriginal articles (n = 4), and non-English language (n = 1). Among the remaining 16 articles, we further excluded studies lacking quantitative results (n = 5) and those without control groups (n = 2). Finally, 9 studies were included in the analysis (Supplementary Figure 1 (650.6KB, pdf) ).24,26–33
The 9 included studies were published between 2009 and 2021, with 5 (55.6%) from the United States, 3 (33.3%) from Korea, and 1 (11.1%) from multiple countries. Study designs included 6 (66.7%) cohort studies, 2 (22.2%) case-crossover studies, and 1 (11.1%) RCT. All observational studies (n = 8; 88.9%) used electronic health record data, whereas the RCT used clinical trial data.
Sample sizes across studies ranged from 1,139 to 3,352,015 patients. Age stratification also differed among studies: some studies analyzed broad age groups (eg, all ages, older/younger than 20 years), whereas others employed more granular classifications (eg, 1-4, 5-8, 9-12, 13-16, and 17-21 years). The sex distribution in most studies showed a slight predominance of female participants, with female proportions ranging from 45.7% to 60.5%, except for 2 studies24,33 that did not report sex ratios. The assessment of NPE outcomes varied considerably across studies. Studies evaluated diverse NPE categories including affective disorders, neuropsychiatric symptoms, anxiety or stress disorders, schizophrenia or psychotic disorders, and suicide-related behaviors. Follow-up periods also varied across studies, ranging from 2 to 56 days after oseltamivir administration (Table 1).
TABLE 1.
Characteristics of Studies Investigating Neuropsychiatric Events Following Oseltamivir Treatment
| Study | Country | Study design | Database source (duration) | Population, n | Sex | Outcome | Follow-up period, days |
|---|---|---|---|---|---|---|---|
| Blumentals and Song,26 2007 | US | Cohort | MarketScan (2000-2006) | Diagnosis of influenza (ICD-9-CM 487.xx)
|
Male: 44.9% Female: 55.1% |
|
|
| Smith and Sacks,27 2009 | US | Cohort | US health care database (1999-2005) | Diagnosis of influenza (ICD-9-CM 487.xx)
|
Male: 46.9% Female: 53.1% |
|
|
| Casscells et al,28 2009 | US | Cohort | TRICARE (2006-2007) | Diagnosis of influenza (ICD-9-CM 487.xx)
|
Male: 54.3% Female: 45.7% |
|
30 |
| Greene et al,29 2013 | US | Cohort | Vaccine Safety Datalink (2007-2010) | Diagnosis of influenza (ICD-9-CM 487.x and 488.xx) or positive influenza test
|
Male: 45.8% Female: 54.2% |
|
|
| Jones et al,24 2018 | Multi | RCT | Clinical study reports (∼2017) | All prophylaxis randomized studies of oseltamivir for influenza >13 y: 3,434 | No information |
|
56 |
| Harrington et al,33 2018 | US | Case-crossover | MarketScan (2009-2013) | Oseltamivir exposure from pharmacy dispensing record 1-18 y: 1,139 |
No information | Suicide and suicide attempt |
|
| Kang et al,30 2019 | Korea | Case-crossover | National sample cohort (2009-2013) | Oseltamivir exposure from prescription record (ATC J05AH02)
|
Male: 39.5% Female: 0.5% |
Neuropsychiatric symptoms |
|
| Huh et al,31 2020 | Korea | Cohort | Korean National Health Insurance Service (2009-2017) | Diagnosis of influenza (ICD-10-CM J09, J10, and J11)
|
Male: 48.9% Female: 51.1% |
|
30 |
| Kang et al,32 2021 | Korea | Cohort | National sample cohort (2003-2013) | Diagnosis of influenza (ICD-10-CM J09-J11)
|
Male: 48.3% Female: 51.7% |
|
|
ATC = Anatomical Therapeutic Chemical; CNS = central nervous system; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification; RCT = randomized controlled trial.
FINDINGS FROM META-ANALYSIS
In the analysis of overall NPE risk, oseltamivir use significantly associated with a lower incidence of NPE across all age groups (RR = 0.83; 95% CI = 0.72-0.97). However, no significant difference was observed in patients younger than 20 years (RR = 0.87; 95% CI = 0.72-1.05) (Figure 1).
FIGURE 1.
Forest Plot of RRs for Neuropsychiatric Events Associated With Oseltamivir Use by Age Groups
A 2-stage model was used in part A. In the first stage, we obtained the overall effect size estimate of multiple measures within all studies using a 3-level meta-analysis. In the second stage, we pooled and obtained the overall effect size estimate using 1 effect size from each study. For Greene et al, although the total sample size for participants younger than 20 years was 23,298, we used data from the subgroup analysis of ages 2-19 years (n = 21,088) as this provided the odds ratio values. Studies that did not allow for discrete analysis of the younger than 20 age group, such as Jones et al, were excluded from the age under 20 years analysis in part B.
RR = risk ratio.
In subgroup analyses by outcome measure, all age groups showed a significant association with lower risk reduction in suicide and suicide attempts after oseltamivir use (RR = 0.60; 95% CI = 0.46-0.77) (Figure 2). In other outcome measures, no significant differences were found (Figure 2). Among patients aged younger than 20 years, a significant association with a lower risk was shown in schizophrenia or other psychotic disorders (RR = 0.75; 95% CI = 0.61-0.93) (Figure 3).
FIGURE 2.
Forest Plot of RRs for Specific Neuropsychiatric Events Associated With Oseltamivir Use in All Ages
We categorized outcomes into 5 main groups: (A) affective disorders (affective disorder, bipolar disorder, and depression), (B) neuropsychiatric symptoms (altered state of consciousness, central nervous system disorders and neuropsychiatric symptoms, confusional state, delirium, hallucination, and neuropsychiatric symptoms), (C) anxiety or stress disorders (anxiety and stress disorder), (D) schizophrenia or psychotic disorders (schizophrenia and psychotic disorder), and (E) suicide and suicidal behavior (suicide and suicide attempt).
RR = risk ratio.
FIGURE 3.
Forest Plot of RRs for Specific Neuropsychiatric Events Associated With Oseltamivir Use in Patients Younger Than 20 Years
We categorized outcomes into 5 main groups: (A) affective disorders (affective disorder, bipolar disorder, and depression), (B) neuropsychiatric symptoms (altered state of consciousness, central nervous system disorders and neuropsychiatric symptoms, confusional state, delirium, hallucination, and neuropsychiatric symptoms), (C) schizophrenia or psychotic disorders (schizophrenia and psychotic disorder); and (D) suicide and suicidal behavior (suicide and suicide attempt).
RR = risk ratio.
MODERATOR ANALYSIS
Meta-regression analyses showed no significant effects of potential moderators, including age, sex, sample size, region, and study design, suggesting that these covariates did not have moderating roles in our main findings (Supplementary Table 3 (650.6KB, pdf) ).
PUBLICATION BIAS ASSESSMENT
Visual inspection of funnel plots revealed symmetric distribution of study results, suggesting no substantial publication bias (Supplementary Figure 2 (650.6KB, pdf) ). These findings were further supported by both the Egger test and Begg-Mazumdar rank correlation test, with all P values greater than 0.05.
QUALITY ASSESSMENT
The risk of bias assessment using ROBINS-I is presented in Supplementary Figure 3 (650.6KB, pdf) . Overall, most studies demonstrated a low risk of bias across multiple domains, particularly in selection of participants (D2), classification of interventions (D3), measurement of outcomes (D6), and selection of reported results (D7). However, 3 studies30,31,33 showed a moderate risk of bias because of confounding (D1). All studies except that of Jones et al24 showed a moderate risk of bias owing to deviations from intended interventions (D4). The study by Jones et al,24 which pooled data from 4 clinical trials, had insufficient information available to assess bias from deviations from intended interventions (D4) and missing data (D5).
Discussion
Despite oseltamivir’s proven efficacy and safety in reducing transmission and severity of infection, there have been lingering concerns about its potential side effects, which include psychological or psychiatric side effects. This systematic review and meta-analysis suggests that the use of oseltamivir is not associated with adverse NPEs. Oseltamivir is a drug that will likely remain in use in the future, and antiviral use may be an important part of influenza-related pandemic response because suitable vaccines may not be available at the beginning of a pandemic.34
Some observational studies and case reports suggested an association between oseltamivir use and NPEs.30,35,36 Some of the findings from other studies may be different because of different study settings, and the scope and criteria for NPEs may vary between studies. In addition, the analytical approaches and statistical models used vary across the studies. However, individual studies may have inherent limitations and may be confounded by indications if NPE-related risk factors are not adequately controlled. Case-crossover designs are effective in controlling for time-invariant individual characteristics, but they may be vulnerable to such bias if the temporal relationship between disease onset and treatment exposure is not carefully identified. In prospective clinical studies, however, compared with those receiving placebo or no antiviral drugs, patients receiving oseltamivir showed no indication of developing NPEs.27,37 These previous studies had important limitations, including small sample sizes, infrequent outcome events, short-term follow-up periods, and an inability to distinguish NPEs that arise from oseltamivir as compared with those that arise from influenza itself.33 Thus, our findings overcome the limitations of previous studies and contributes to a comprehensive decision-making approach between oseltamivir and adverse neuropsychiatric symptoms.
In previous studies, reports of suicide attempts, delirium, and other psychiatric events, particularly among children and adolescents, have raised concerns about the safety of oseltamivir.33 These reports documented unusual behaviors, such as psychosis, and/or suicide attempts, which contributed to a revision of warning labels to include the risk of such events starting in 2006.33 Although these earlier reports highlighted the potential association between oseltamivir and NPEs, our study found that the occurrence of NPEs was not notably higher in individuals treated with oseltamivir across all age groups, including those younger than 20 years. In fact, the occurrence of adverse effects related to suicide and suicide attempts was lower across all age groups. Additionally, we observed a reduction in the frequency of schizophrenia and other psychotic disorders in patients younger than 20 years. These findings suggest that, although earlier reports may have raised concerns, our study does not support the association between oseltamivir and a heightened risk of NPEs. Moreover, secondary analyses of RCTs and several cohort studies among pediatric patients have similarly not identified any association, further supporting the safety of oseltamivir in the treatment of influenza.17,26,28 This suggests that our study reaffirms the safety of oseltamivir in the treatment of influenza.
There are some possible explanations to support our findings. Influenza can cause damage through viral replication directly and damage through immune system cytokine storms indirectly. Further, it can damage a variety of cells and tissues, including those of the nervous system.38–43 Although past concerns about NPEs have primarily stemmed from anecdotal reports and poorly controlled observational studies, more rigorous analyses, such as this meta-analysis, have shown that oseltamivir does not increase the risk of specific NPEs. The most likely mechanism of action for the previously observed NPEs may be the neuroinflammatory effects of influenza itself rather than the pharmacological action of oseltamivir.
Oseltamivir use in the treatment of influenza emphasizes the need for vigilance during and after treatment, especially among the pediatric and adolescent populations given other reports.44,45 Our findings suggest that oseltamivir does not increase the risk of NPEs when used to treat influenza. However, the long-term potential risks and benefits of treatment should still be considered to provide better patient care.
LIMITATIONS
This study has several limitations. First, the studies included in this review used a variety of designs, including cohort studies, case-crossover studies, and RCTs. This diversity in study designs may result in differences in data-collection methods, outcome-reporting formats, controlling for confounding variables, and risk-assessment methods, all of which may limit the consistency of the findings and reduce reliability. Second, the inability to distinguish between new-onset adverse events and the exacerbation of pre-existing conditions may have resulted in misclassification of some outcomes. Third, data on the age group younger than 20 years were not uniformly reported across all studies, which may limit the reliability of the results of age-specific analyses. Fourth, the follow-up period varied from 2 to 56 days across studies, and this difference may not consistently reflect the temporal effects on assessing NPEs. Fifth, there may be residual confounding because of unmeasured factors such as socioeconomic status or influenza severity. Finally, the lack of clear data on oseltamivir usage (dose and duration of treatment) may limit the elucidation of the relationship between drug dose and NPEs.
Although there are existing studies on common side effects of oseltamivir, there have been no comprehensive studies that examined adverse NPEs. To our knowledge, this is the first study to address such gaps. To overcome the limitations of existing studies in the future, it will be necessary to establish strategies to standardize research designs and minimize biases.
Conclusions
This systematic review and meta-analysis is the first study that found no evidence supporting increased adverse NPEs or behavioral events with oseltamivir use. Although these findings provide important evidence supporting the neuropsychiatric safety profile of oseltamivir, further research is needed to confirm these protective effects.
Disclosures
The authors declare that no financial support was received for the research, authorship, and/or publication of this article. Drs Jeong and Lee contributed equally.
Acknowledgments
We thank Korea University, Seoyeong University, Konyang University, Yale School of Medicine, and the University of Connecticut for their support in this research.
References
- 1.World Health Organization . Fact sheet: Influenza (seasonal). Accessed December 7, 2024. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
- 2.Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258-64. doi: 10.1016/j.amjmed.2007.10.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med. 2010;38(4)(suppl):e91-7. doi: 10.1097/CCM.0b013e3181c92eeb [DOI] [PubMed] [Google Scholar]
- 4.Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7(35):iii-iv, xi. doi: 10.3310/hta7350 [DOI] [PubMed] [Google Scholar]
- 5.Caceres CJ, Seibert B, Cargnin Faccin F, Cardenas-Garcia S, Rajao DS, Perez DR. Influenza antivirals and animal models. FEBS Open Bio. 2022;12(6):1142-65. doi: 10.1002/2211-5463.13416 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.National Institute for Clinical Excellence . Guidance on the Use of Zanamivir, Olsetamivir and Amantadine for the Treatment of Influenza: Technology Appraisal Guidance. National Institute for Clinical Excellence; 2010. [Google Scholar]
- 7.Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119(4):681-90. doi: 10.1021/ja963036t [DOI] [PubMed] [Google Scholar]
- 8.Treanor JJ, Hayden FG, Vrooman PS, et al. ; US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA. 2000;283(8):1016-24. doi: 10.1001/jama.283.8.1016 [DOI] [PubMed] [Google Scholar]
- 9.Jones JC, Yen HL, Adams P, Armstrong K, Govorkova EA. Influenza antivirals and their role in pandemic preparedness. Antiviral Res. 2023;210:105499. doi: 10.1016/j.antiviral.2022.105499 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729-37. doi: 10.1016/S0140-6736(14)62449-1 [DOI] [PubMed] [Google Scholar]
- 11.Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents. 2010;35(5):461-7. doi: 10.1016/j.ijantimicag.2009.12.023 [DOI] [PubMed] [Google Scholar]
- 12.Fares R, Zgheib A, Hallit R, Hallit S. Oseltamivir-induced behavioral changes in a female Lebanese adolescent: A case report of a usual drug with unusual side effect. Future Sci OA. 2020;6(9):FSO602. doi: 10.2144/fsoa-2019-0162 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ho LN, Chung JP, Choy KL. Oseltamivir-induced mania in a patient with H1N1. Am J Psychiatry. 2010;167(3):350. doi: 10.1176/appi.ajp.2009.09101421 [DOI] [PubMed] [Google Scholar]
- 14.Chung S, Joung YS. Oseltamivir (tamiflu) induced depressive episode in a female adolescent. Psychiatry Investig. 2010;7(4):302-4. doi: 10.4306/pi.2010.7.4.302 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fuyuno I. Tamiflu side effects come under scrutiny. Nature. 2007;446(7134):358-9. doi: 10.1038/446358a [DOI] [PubMed] [Google Scholar]
- 16.Jhon M, Kim JW, Kang HJ, et al. Delayed onset of manic symptoms in a patient with influenza A (H1N1) after administration of oseltamivir (Tamiflu): A case report. Clin Psychopharmacol Neurosci. 2021;19(1):166-9. doi: 10.9758/cpn.2021.19.1.166 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(apr09 2):g2545. doi: 10.1136/bmj.g2545 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Arya S, Kaji AH, Boermeester MA. PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg. 2021;156(8):789-90. doi: 10.1001/jamasurg.2021.0546 [DOI] [PubMed] [Google Scholar]
- 19.Orsini N. From floated to conventional confidence intervals for the relative risks based on published dose-response data. Comput Methods Programs Biomed. 2010;98(1):90-3. doi: 10.1016/j.cmpb.2009.11.005 [DOI] [PubMed] [Google Scholar]
- 20.Shim SR, Kim SJ, Lee J. Diagnostic test accuracy: Application and practice using R software. Epidemiol Health. 2019;41:e2019007. doi: 10.4178/epih.e2019007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Van den Noortgate W, López-López JA, Marín-Martínez F, Sánchez-Meca J. Three-level meta-analysis of dependent effect sizes. Behav Res Methods. 2013;45(2):576-94. doi: 10.3758/s13428-012-0261-6 [DOI] [PubMed] [Google Scholar]
- 22.Rhee TG, Shim SR, Forester BP, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: A systematic review and meta- analysis. JAMA Psychiatry. 2022;79(12):1162-72. doi: 10.1001/jamapsychiatry.2022.3352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Shim SR, Kim SJ. Intervention meta-analysis: Application and practice using R software. Epidemiol Health. 2019;41:e2019008. doi: 10.4178/epih.e2019008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Jones M, Tett SE, Del Mar C. Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports. Pharmacoepidemiol Drug Saf. 2018;27(11):1217-22. doi: 10.1002/pds.4651 [DOI] [PubMed] [Google Scholar]
- 25.Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. MedGenMed. 2007;9(4):23. [PMC free article] [PubMed] [Google Scholar]
- 27.Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract. 2009;63(4):596-605. doi: 10.1111/j.1742-1241.2009.02010.x [DOI] [PubMed] [Google Scholar]
- 28.Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21(1):79-89. doi: 10.1515/IJAMH.2009.21.1.79 [DOI] [PubMed] [Google Scholar]
- 29.Greene SK, Li L, Shay DK, et al. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. Pharmacoepidemiol Drug Saf. 2013;22(4):335-44. doi: 10.1002/pds.3363 [DOI] [PubMed] [Google Scholar]
- 30.Kang HR, Lee EK, Kim WJ, Shin JY. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: A nationwide population-based case-crossover study. J Antimicrob Chemother. 2019;74(2):453-61. doi: 10.1093/jac/dky445 [DOI] [PubMed] [Google Scholar]
- 31.Huh K, Kang M, Shin DH, Hong J, Jung J. Oseltamivir and the risk of neuropsychiatric events: A national, population-based study. Clin Infect Dis. 2020;71(9):e409-14. doi: 10.1093/cid/ciaa055 [DOI] [PubMed] [Google Scholar]
- 32.Kang HR, Jang SC, Shin JY. Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: A nationwide population-based cohort study. Expert Opin Drug Saf. 2021;20(2):245-53. doi: 10.1080/14740338.2021.1850690 [DOI] [PubMed] [Google Scholar]
- 33.Harrington R, Adimadhyam S, Lee TA, et al. The relationship between oseltamivir and suicide in pediatric patients. Ann Fam Med. 2018;16(2):145-8. doi: 10.1370/afm.2183 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hurt AC, Kelly H. Debate regarding oseltamivir use for seasonal and pandemic influenza. Emerg Infect Dis. 2016;22(6):949-55. doi: 10.3201/eid2206.151037 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Hoffman KB, Demakas A, Erdman CB, Dimbil M, Doraiswamy PM. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013;347:f4656. doi: 10.1136/bmj.f4656 [DOI] [PubMed] [Google Scholar]
- 36.Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior incidence in 10–19 year old patients administered neuraminidase inhibitors. PLoS One. 2015;10(7):e0129712. doi: 10.1371/journal.pone.0129712 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006 [DOI] [PubMed] [Google Scholar]
- 38.Li Z, Li L, Zhao S, et al. Re-understanding anti-influenza strategy: Attach equal importance to antiviral and anti-inflammatory therapies. J Thorac Dis. 2018;10(S9)(suppl 19):S2248-59. doi: 10.21037/jtd.2018.03.169 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Holt PG, Strickland DH, Wikström ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8(2):142-52. doi: 10.1038/nri2236 [DOI] [PubMed] [Google Scholar]
- 40.Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363-73. doi: 10.1056/NEJMra050740 [DOI] [PubMed] [Google Scholar]
- 41.Bird NL, Olson MR, Hurt AC, et al. Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses. PLoS One. 2015;10(6):e0129768. doi: 10.1371/journal.pone.0129768 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: Immunopathology in influenza virus infection. Immunol Cell Biol. 2007;85(2):85-92. doi: 10.1038/sj.icb.7100026 [DOI] [PubMed] [Google Scholar]
- 43.Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2007;(1):CD002744. doi: 10.1002/14651858.CD002744.pub2 [DOI] [PubMed] [Google Scholar]
- 45.Chen R, Fang Z, Huang Y. Neuropsychiatric events in an adult patient with influenza A (H3N2) treated with oseltamivir (Tamiflu): A case report. BMC Infect Dis. 2019;19(1):224. doi: 10.1186/s12879-019-3827-4 [DOI] [PMC free article] [PubMed] [Google Scholar]



